|
US3254124A
(en)
|
1962-06-29 |
1966-05-31 |
Parke Davis & Co |
Aminoketones and methods for their production
|
|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
US4670459A
(en)
|
1984-10-03 |
1987-06-02 |
Merrell Dow Pharmaceuticals Inc. |
Method of alleviating withdrawal symptoms
|
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
|
DE19619665C2
(de)
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemattrennung von Ketamin
|
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US7001609B1
(en)
|
1998-10-02 |
2006-02-21 |
Regents Of The University Of Minnesota |
Mucosal originated drug delivery systems and animal applications
|
|
US6382204B1
(en)
|
1999-10-14 |
2002-05-07 |
Becton Dickinson And Company |
Drug delivery system including holder and drug container
|
|
US6962151B1
(en)
|
1999-11-05 |
2005-11-08 |
Pari GmbH Spezialisten für effektive Inhalation |
Inhalation nebulizer
|
|
SI1257648T2
(sl)
|
2000-02-23 |
2016-11-30 |
Amgen Inc. |
Antagonistični selektivni vezavni agensi za osteoprotegerin vezavni protein
|
|
BRPI0002693B8
(pt)
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
EP1551393A4
(en)
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
CA2506615A1
(en)
|
2002-11-18 |
2004-06-03 |
Yaupon Therapeutics, Inc. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US7713440B2
(en)
|
2003-10-08 |
2010-05-11 |
Lyotropic Therapeutics, Inc. |
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
US7928132B2
(en)
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
|
PT1928405E
(pt)
|
2005-09-28 |
2014-10-20 |
Auris Medical Ag |
Composições farmacêuticas para o tratamento de distúrbios do ouvido interno
|
|
CN101466364A
(zh)
*
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
|
CN101765582A
(zh)
|
2007-04-26 |
2010-06-30 |
奥斯拜客斯制药有限公司 |
氘标记的氯胺酮
|
|
US20120225949A1
(en)
*
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US20110038807A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
WO2013138322A1
(en)
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
AU2013305580A1
(en)
|
2012-08-23 |
2015-04-09 |
Stuart L. Weg |
Anxiolytic composition, formulation and method of use
|
|
SG11201507358VA
(en)
|
2013-03-15 |
2015-10-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
US20140275278A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
AU2014250756B2
(en)
|
2013-04-12 |
2019-03-07 |
Icahn School Of Medicine At Mount Sinai |
Method for treating post-traumatic stress disorder
|
|
HRP20211629T1
(hr)
|
2013-09-13 |
2022-02-04 |
National University Corporation Chiba University |
Primjena r-ketamina i njegove soli kao lijekova
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
KR101705446B1
(ko)
|
2014-04-29 |
2017-02-09 |
가톨릭대학교 산학협력단 |
면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
|
|
EP3179993B1
(en)
|
2014-08-13 |
2021-01-20 |
Janssen Pharmaceutica NV |
Esketamine for use in a method for the treatment of depression
|
|
CA2961208A1
(en)
|
2014-09-15 |
2016-03-24 |
Janssen Pharmaceutica Nv |
Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
RU2771275C2
(ru)
|
2014-11-04 |
2022-04-29 |
Аморса Терапьютикс, Инк. |
Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20200297734A1
(en)
|
2015-06-19 |
2020-09-24 |
Melt Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for anesthesiological applications
|
|
KR101964571B1
(ko)
|
2015-06-19 |
2019-04-02 |
해로우 헬스 인코포레이티드 |
마취용 약학 조성물
|
|
AU2016288188B2
(en)
|
2015-06-27 |
2021-08-05 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
WO2017087691A1
(en)
|
2015-11-17 |
2017-05-26 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
AU2017238858A1
(en)
|
2016-03-25 |
2018-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
|
US20200261442A1
(en)
|
2016-08-26 |
2020-08-20 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
JP7096813B2
(ja)
|
2016-08-26 |
2022-07-06 |
エクシーバ ゲーエムベーハー |
組成物及びその方法
|
|
WO2018075481A1
(en)
|
2016-10-17 |
2018-04-26 |
Yale University |
Compounds, compositions and methods for treating or preventing depression and other diseases
|
|
US20190240184A1
(en)
|
2016-10-27 |
2019-08-08 |
National University Corporation Chiba University |
Pharmaceutical applications for (s)-norketamine and salts thereof
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
JP6856840B2
(ja)
|
2016-12-27 |
2021-04-14 |
アクション メディカル テクノロジーズ，エルエルシーＡｃｔｉｏｎ Ｍｅｄｉｃａｌ Ｔｅｃｈｎｏｌｏｇｉｅｓ，Ｌｌｃ |
注入器、および注入器を動作させる方法
|
|
KR20190124722A
(ko)
|
2017-01-31 |
2019-11-05 |
파올로 엘. 만프레디 |
신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체
|
|
US11478467B2
(en)
|
2017-05-04 |
2022-10-25 |
Sreenivasarao Vepachedu |
Targeted drug rescue with novel compositions, combinations, and methods thereof
|
|
KR102608479B1
(ko)
|
2017-05-25 |
2023-12-01 |
글리테크 엘엘씨. |
Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
|
|
JP7265990B2
(ja)
|
2017-09-27 |
2023-04-27 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US10869838B2
(en)
|
2017-10-10 |
2020-12-22 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
US10441544B2
(en)
|
2017-10-10 |
2019-10-15 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
CN107823195A
(zh)
|
2017-11-24 |
2018-03-23 |
无锡市精神卫生中心 |
R‑氯胺酮在抑郁症急性期治疗中的应用
|
|
EP3505509A1
(en)
|
2017-12-29 |
2019-07-03 |
Université de Liège |
Methods for the preparation of arylcycloalkylamine derivatives
|
|
KR20260028033A
(ko)
|
2018-01-10 |
2026-03-03 |
엑스더블유파마 리미티드 |
케타민의 전구약물, 및 이의 조성물 및 용도
|
|
CN118453559A
(zh)
|
2018-02-15 |
2024-08-09 |
国立大学法人千叶大学 |
炎症性疾病或骨病的预防或治疗剂及医药组合物
|
|
WO2019169165A1
(en)
|
2018-02-28 |
2019-09-06 |
Novocine Therapeutics, Llc |
Ketamine and ketamine-related compounds for the treatment of neurological disorders
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
CA3099293A1
(en)
|
2018-05-04 |
2019-11-07 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
BR112020023882A2
(pt)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
método para tratar transtorno depressivo maior
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
US11865088B2
(en)
|
2018-10-05 |
2024-01-09 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
EP3863617A1
(en)
|
2018-10-11 |
2021-08-18 |
Clexio Biosciences Ltd. |
Esketamine for use in treating major depressive disorder
|
|
US20220110889A1
(en)
|
2018-12-27 |
2022-04-14 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
|
|
FI3908570T3
(fi)
|
2019-01-11 |
2024-02-13 |
Alar Pharmaceuticals Inc |
Ketamiinipamoaatti ja sen käyttö
|
|
WO2020198039A1
(en)
|
2019-03-23 |
2020-10-01 |
Sermone Sandra |
Ketamine for treatment of sensory processing deficits
|
|
WO2020212510A1
(en)
|
2019-04-16 |
2020-10-22 |
Janssen Pharmaceutica Nv |
Synthetic methods of preparing esketamine
|
|
WO2020232274A1
(en)
|
2019-05-15 |
2020-11-19 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
US11007200B2
(en)
|
2019-08-21 |
2021-05-18 |
MediSynergics, LLC |
Cycloalkyl-diamines for the treatment of pain
|
|
WO2021121366A1
(en)
|
2019-12-20 |
2021-06-24 |
Alar Pharmaceuticals Inc. |
Long-acting injectable formulations of ketamine pamoate salts
|
|
CN115190815B
(zh)
|
2019-12-26 |
2024-06-18 |
吉尔伽美什制药公司 |
芳基环己基胺衍生物及其在精神障碍的治疗中的用途
|
|
US12268658B2
(en)
|
2019-12-30 |
2025-04-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
EP4125836A1
(en)
|
2020-03-27 |
2023-02-08 |
Homeostasis Therapeutics, Limited |
Method of treatment for anorexia nervosa, bulimia and related clinical syndromes
|
|
CN115916174A
(zh)
|
2020-04-07 |
2023-04-04 |
纽约市哥伦比亚大学理事会 |
用于预防应激诱导的恐惧、抑郁样和焦虑样行为的组合物和方法
|
|
US12128012B2
(en)
|
2020-05-15 |
2024-10-29 |
University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
|
WO2021252971A2
(en)
|
2020-06-12 |
2021-12-16 |
Bexson Biomedical, Inc. |
Systems and devices for controlled drug delivery
|
|
CA3182424A1
(en)
|
2020-06-17 |
2021-12-23 |
Irving William Wainer |
Hydroxynorketamine analogues, compositions comprising same and methods of use thereof
|
|
WO2023064363A1
(en)
|
2021-10-12 |
2023-04-20 |
Perception Neuroscience, Inc. |
R-ketamine salts and methods of use thereof
|
|
JP2025509517A
(ja)
|
2022-03-14 |
2025-04-11 |
パーセプション ニューロサイエンス，インコーポレイティド |
Ｒ－ケタミンの医薬製剤
|
|
US20250281426A1
(en)
|
2022-04-26 |
2025-09-11 |
Yichang Humanwell Pharmaceutical Co., Ltd. |
R-ketamine liquid preparation and use thereof
|
|
US20260027068A1
(en)
|
2022-12-28 |
2026-01-29 |
Perception Neuroscience, Inc. |
Methods of administering r-ketamine
|